Tempest Therapeutics
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2000 Sierra Point Pkwy Ste 400, Brisbane...Phone Number
(415) 798-8589Website
www.tempesttx.comRevenue
-Stock Symbol
TPSTIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
2
1
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company headquartered in Brisbane, California, and publicly traded on Nasdaq under the ticker TPST. The company develops next-generation in vivo CAR-T therapies for autoimmune diseases and cancer, using a proprietary mRNA lipid nanoparticle delivery platform. Its pipeline includes TPST-4003, a dual-target CD19/BCMA CAR-T therapy, and TPST-2003, a similar therapy being developed for relapsed/refractory multiple myeloma in partnership with Novatim Immune Therapeutics. Tempest is also exploring applications in conditions such as myasthenia gravis and multiple sclerosis.Explore more
Tempest Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tempest Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Tempest Therapeutics recently announced quarterly report
Click to see if Tempest Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Tempest Therapeutics launches new products
Check if Tempest Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Tempest Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Tempest Therapeutics
Tempest Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Tempest Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Tempest Therapeutics
Find more new buyers
Compare Similar Companies to Tempest Therapeutics
Compare insights from companies similar to Tempest Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Tempest Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Tempest Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Tempest Therapeutics.
Tempest Therapeutics financials insights
Gather financial insights about Tempest Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Series A
$5M
2018
Series B
$70M
2022
Share Placement
$15M
2026
Stock/Share Issuance
$2M
Stock/Share Issuance
$4.1M
Tempest Therapeutics Tech Stack
A closer look at the technologies used by Tempest Therapeutics
Most Recent Scoops
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Person-Based
Business Development
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
Tempest Therapeutics News & Media
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
Accomplished finance and enterprise executive with over 20 years of global leadership in multinational and Fortune 500 companies Accomplished finance and enterprise executive with over 20 years of global leadership in multinational and Fortune 500 companiesTempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
-Transaction complements Tempest’s existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this yearTempest Therapeutics Announces Up to $7.5 Million Private Placement
$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants $2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrantsTempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
BRISBANE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease, today announced that Matt Angel, Ph.D., Tempest’s President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 2:30 p.m. ET.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Tempest Therapeutics
Sign Up For FreeTo access detailed company insights
Tempest Therapeutics is a clinical-stage biotechnology company headquartered in Brisbane, California, and publicly traded on Nasdaq under the ticker TPST. The company develops next-generation in vivo CAR-T therapies for autoimmune diseases and cancer, using a proprietary mRNA lipid nanoparticle delivery platform. Its pipeline includes TPST-4003, a... Read More
